Introduction
============

Nasopharyngeal carcinoma (NPC), a head and neck malignancy, is prevalent in East and South Asia, where it has a high incidence rate of up to 71%.[@b1-cmar-10-5605] Although the availability of intensity-modulated radiation therapy (IMRT) and adjuvant chemotherapy has partially improved the survival rate of patients, there remains a significant fraction of patients who experience clinical therapy failure, due to local recurrence and distant metastasis.[@b2-cmar-10-5605] Although traditional TNM staging can be used to predict cancer prognosis, it is not very effective. In recent years, studies have focused on biomarkers with potential use in targeted treatment and predicting prognosis. Although several molecular markers have been identified to predict a favorable prognosis in NPC,[@b3-cmar-10-5605]--[@b6-cmar-10-5605] it will be of great value for NPC patients if more potent biomarkers can be identified that not only aid in the prediction of prognosis, but also provide promising therapeutic targets for therapy.

Autophagy is a programmed prosurvival mechanism in eukaryotic cells that serves to degrade cytoplasmic organelles in order to sustain cellular metabolism.[@b7-cmar-10-5605] Recent evidence has suggested that dysfunction in autophagy is associated with a wide range of diseases.[@b8-cmar-10-5605] Autophagy has dual functions in tumorigenesis: it plays a tumor-suppressive role when autophagic cell death is induced via several mechanisms,[@b9-cmar-10-5605],[@b10-cmar-10-5605] and a tumor-promoting role by sustaining cancer cell survival in an energy-deficient environment.[@b11-cmar-10-5605],[@b12-cmar-10-5605] Clinical studies in various types of cancer demonstrated that either low or high expression of autophagy-related proteins was associated with an adverse prognosis.[@b13-cmar-10-5605]--[@b15-cmar-10-5605] Hence, the relationship between autophagy and clinical prognosis remains controversial.

TP53-inducible glycolysis and apoptosis regulator (*TIGAR*), as a target of *P53*, plays an essential role in apoptosis and autophagy.[@b16-cmar-10-5605],[@b17-cmar-10-5605] It has been reported that *TIGAR* regulates autophagy by regulating the upstream genes of reactive oxygen species (ROS) responses through inhibiting glycolysis, and that this process may be interrupted by ectopic supplementation of nicotinamide adenine dinucleotide phosphate.[@b16-cmar-10-5605] *TIGAR* can also regulate intracellular ROS levels by regulating glucose metabolism, and promote cell survival and DNA damage repair in response to DNA damage.[@b18-cmar-10-5605]--[@b20-cmar-10-5605] Previous studies have demonstrated that *TIGAR* is also associated with the regulation of cell cycle and metastasis-related proteins and may play an important role in the proliferation, invasion, and metastasis of tumor cells.[@b21-cmar-10-5605] Moreover, various investigations have reported that TIGAR expression is significantly elevated in human tumors, such as colon cancer, breast cancer, and glioblastoma.[@b22-cmar-10-5605]--[@b24-cmar-10-5605] Therefore, TIGAR is likely to play a significant role in oncogenesis and may be a potential therapeutic target for cancer treatment. To the best of our knowledge, the mechanism of action of TIGAR in NPC occurrence and development has not yet been clarified, and how TIGAR expression level may affect the prognosis of NPC patients also remains unclear.

Microtubule-associated protein 1 light chain 3 (*LC3B*) is a well-established marker of autophagic activity in cancer cells. The determination of LC3B expression is frequently performed by immunohistochemistry. Therefore, in the present study, we detected the expression levels of TIGAR and LC3B in NPC tissue samples via immunohistochemistry, and investigated the association of TIGAR and/or LC3B protein expression with clinicopathological features and prognosis using log-rank and Cox regression analyses, with the aim of identifying the relationship between TIGAR and LC3B expression levels and the clinical outcomes of NPC patients.

Materials and methods
=====================

Immunohistochemical staining
----------------------------

Immunohistochemical staining was performed with rabbit anti-TIGAR (dilution, 1:400; Abcam, Cambridge, UK, ab37910) and mouse anti-LC3B (dilution 1:200; Cell Signaling Technology, Inc., Danvers, MA, USA, \#3868) antibodies. In the negative control group, the primary antibody was replaced by PBS. Each sample was graded according to the intensity and extent of staining. The intensity of staining was scored as 0 (no staining), 1 (weak staining), 2 (warm staining), or 3 (strong staining). The percentage of positively stained tumor cells was scored as 0 (0%), 1 (1%--25%), 2 (26%--50%), 3 (51%--75%), or 4 (76%--100%). The intensity score × the percentage score was used to obtain the final overall score, and the specimens were classified into two groups according to overall score. Samples were considered LC3B− with a score of 0--5 or LC3B+ with a score of 6--12; samples were considered TIGAR− with a score of 0--5, or TIGAR+ with a score of 6--12. All slides were assessed independently by two pathologists blinded to patient identity and clinical outcome.

Clinical data and treatment
---------------------------

Patient data for this study were gathered between January 2012 and December 2015. This study obtained the ethical approval of Southwest Medical University (reference number: k2017041) and written informed consent was obtained from all patients. All patients were restaged according to the seventh edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) system.[@b25-cmar-10-5605] Patients with the following criteria were included: NPC confirmed by pathological diagnosis; no prior history of radiotherapy, chemotherapy, or oncological surgery; Karnofsky score 70; received IMRT at the Affiliated Hospital of Southwest Medical University; and regular follow-up data were available. Patients with the following criteria were excluded: uncontrolled infection; previous receipt of any anticancer therapy; pregnancy or lactation; prior malignancy; or unsuitable for chemotherapy due to a deficiency of the liver, kidney, lung, or heart.

Baseline examinations included thoracic and abdominal computed tomography scans, nasopharyngeal and neck magnetic resonance imaging, nasopharyngeal fiberscope analysis, and bone scanning. All patients were treated with definitive IMRT. The treatment regimens included platinum-based induction chemotherapy and concurrent chemoradiotherapy. The induction chemotherapy consisted of paclitaxel 175 mg/m^2^ (day 1) and cisplatin 75 mg/m^2^ (day 1), or fluorouracil 1,000 mg/m^2^/day through continuous IV infusion for 96 hours and cisplatin 75 mg/m^2^ (day 1). Two cycles were administered at 3-week intervals, followed by IMRT performed concurrently with 40 mg/m^2^/week cisplatin.

Target volumes for the nasopharyngeal and nodal regions were defined according to the recommendations of the International Commission on Radiation Units and Measurements 50,[@b26-cmar-10-5605] 62,[@b27-cmar-10-5605] 71,[@b28-cmar-10-5605] and 83[@b29-cmar-10-5605] guidelines. The doses prescribed on planning gross tumor volume of nasopharynx, planning gross tumor volume of neck metastasis lymph node, planning clinical target volume of high-risk area, and planning clinical target volume of low-risk area were 70, 70, 64, and 54 Gy (in 33 fractions), respectively. The plan was delivered once daily, with a total of five fractions per week.

Follow-up and statistical analyses
----------------------------------

The duration of follow-up was calculated from the date of diagnosis to the date of death or the date of last follow-up examination for the surviving patients. Generally, after the completion of therapy, patients were followed up every 3 months during the first 2 years, and every 6 months during the next 3 years. The median follow-up time for the entire group was 35 months (range, 17--64 months). Overall survival (OS), failure-free survival (FFS), local regional failure-free survival (LR-FFS), and distant failure-free survival (D-FFS) were calculated from the initial diagnosis to death, disease failure, local regional failure, and distant failure, respectively. For patients who survived until the last follow-up, the duration of survival was censored.

Statistics
----------

The association between TIGAR and LC3B expression levels and clinicopathological variables was evaluated using the chi-squared test. The correlation between TIGAR and LC3B expression levels was evaluated using Spearman's correlation analysis. Cumulative recurrence, cumulative metastasis, and survival probability were estimated using Kaplan--Meier analysis, and the statistical significance of differences was assessed by the log-rank test. Prognostic factors for survival were identified using univariate and multivariate Cox regression analyses. In all cases, a two-tailed *P*-value of \<0.05 was considered statistically significant. Statistical analyses were performed using SPSS 17 software.[@b30-cmar-10-5605]

Results
=======

Patient characteristics
-----------------------

A total of 182 NPC cases were assessed in our research. The median age of the patients was 48 years (range, 20--73 years). The patients comprised 128 males and 54 females. A total of 48 patients (26.4%) were initially diagnosed at an early stage (Stage I--II) and 134 (73.6%) at an advanced stage (Stage III--IV). The UICC/AJCC T stage was T1--2 for 97 cases (53.3%) and T3--4 for 85 cases (46.7%). Lymph node metastases were absent in 33 cases (18.1%) and present in 149 cases (81.9%). The WHO pathology classification was grade I for 4 cases (2.2%), grade II for 65 cases (35.7%), and grade III for 113 cases (62.1%). The baseline clinical information of the patients is presented in [Table 1](#t1-cmar-10-5605){ref-type="table"}.

Association of TIGAR and LC3B expressions with clinicopathological characteristics
----------------------------------------------------------------------------------

Cytoplasmic staining was observed for both LC3B and TIGAR. The tumors from 117 patients were TIGAR+ (64.3%), whereas 65 (35.7%) were TIGAR−. There were 56 LC3B+ (30.8%) and 126 LC3B− (69.2%) tumors ([Table 1](#t1-cmar-10-5605){ref-type="table"}). In order to investigate whether the expressions of TIGAR and LC3B in NPC were significantly associated with clinical characteristics, chi-squared tests were used to analyze the relationship between clinicopathological parameters and the expressions of TIGAR and LC3B. However, no statistically significant associations were observed with clinicopathological parameters, including sex, age, pathology classification, lymph node metastasis, and TNM stage, for either TIGAR or LC3B expression (all *P*\>0.05) ([Table 1](#t1-cmar-10-5605){ref-type="table"} and [Figure 1](#f1-cmar-10-5605){ref-type="fig"}).

Correlation between TIGAR and LC3B expressions in NPC patients
--------------------------------------------------------------

We analyzed the correlation between the expression levels of TIGAR and LC3B. The expression of TIGAR was significantly negatively associated with the expression of LC3B (Spearman's correlation analysis, *R*=−0.149, *P*=0.045, [Table 2](#t2-cmar-10-5605){ref-type="table"}).[@b31-cmar-10-5605] Thirty NPC patients presented with TIGAR+/LC3B+ tumors, 26 with TIGAR−/LC3B+, 87 with TIGAR+/LC3B−, and 39 with TIGAR−/LC3B− ([Table 2](#t2-cmar-10-5605){ref-type="table"}).

Association of TIGAR and LC3B expressions with clinical outcomes
----------------------------------------------------------------

We made a comparison of survival outcomes, including of OS, FFS, LR-FFS, and D-FFS rates, depending on the TIGAR and LC3B expressions status of tumors in NPC patients. As shown in [Figures 2](#f2-cmar-10-5605){ref-type="fig"}[](#f3-cmar-10-5605){ref-type="fig"}[](#f4-cmar-10-5605){ref-type="fig"}--[5](#f5-cmar-10-5605){ref-type="fig"}, NPC patients with TIGAR+ tumors had a relatively poor OS (*P*=0.002), FFS (*P*=0.003), LR-FFS (*P*=0.025), and D-FFS (*P*=0.034) rates compared with those with TIGAR− tumors, as determined by Kaplan--Meier survival analyses and log-rank tests. By contrast, patients with LC3B− tumors had a relatively poor FFS (*P*=0.015) and LR-FFS (*P*=0.027) rates compared with those with LC3B+. Although the differences in D-FFS (*P*=0.118) and OS (*P*=0.059) were not statistically significant, the trend was toward an association with poorer OS and D-FFS ([Table 3](#t3-cmar-10-5605){ref-type="table"}).

[Tables 4](#t4-cmar-10-5605){ref-type="table"}[](#t5-cmar-10-5605){ref-type="table"}[](#t6-cmar-10-5605){ref-type="table"}--[7](#t7-cmar-10-5605){ref-type="table"} show the results of the univariate and multivariate Cox proportional hazards analyses for the association of clinicopathological variables with OS, LR-FFS, D-FFS, and FFS. TIGAR+ tumors were associated with poor outcomes, including decreased OS (*P*=0.005, [Table 7](#t7-cmar-10-5605){ref-type="table"}), LR-FFS (*P*=0.035, [Table 4](#t4-cmar-10-5605){ref-type="table"}), D-FFS (*P*=0.041, [Table 5](#t5-cmar-10-5605){ref-type="table"}), and FFS (*P*=0.004, [Table 6](#t6-cmar-10-5605){ref-type="table"}) rates. In multivariate analysis, TIGAR+ was associated with poorer OS (*P*=0.004, [Table 7](#t7-cmar-10-5605){ref-type="table"}), LR-FFS (*P*=0.041, [Table 4](#t4-cmar-10-5605){ref-type="table"}), and FFS (*P*=0.015, [Table 6](#t6-cmar-10-5605){ref-type="table"}), but not with D-FFS (*P*=0.079, [Table 5](#t5-cmar-10-5605){ref-type="table"}). Similarly, LC3B− was associated with a poorer LR-FFS (*P*=0.044, [Table 4](#t4-cmar-10-5605){ref-type="table"}) and FFS (*P*=0.02, [Table 6](#t6-cmar-10-5605){ref-type="table"}) in the univariate and multivariate analyses (*P*=0.05, [Table 4](#t4-cmar-10-5605){ref-type="table"}; *P*=0.03, [Table 6](#t6-cmar-10-5605){ref-type="table"}, respectively), but not with OS (*P*=0.068 in univariate analysis, *P*=0.057 in multivariate analysis, [Table 7](#t7-cmar-10-5605){ref-type="table"}) or D-FFS (*P*=0.126 in univariate analysis, *P*=0.177 in multivariate analysis, [Table 5](#t5-cmar-10-5605){ref-type="table"}). HRs are shown in [Tables 4](#t4-cmar-10-5605){ref-type="table"}[](#t5-cmar-10-5605){ref-type="table"}[](#t6-cmar-10-5605){ref-type="table"}--[7](#t7-cmar-10-5605){ref-type="table"}.

We also analyzed the relationship between the combinations of TIGAR and LC3B expression patterns and patient prognoses. The patterns assessed were LC3B−/TIGAR+, LC3B+/TIGAR+, LC3B+/TIGAR−, and LC3B−/TIGAR−. The subgroup of LC3B−/TIGAR+ tumors (n=87) was associated with poor OS, FFS, LR-FFS, and D-FFS rates (all *P*\<0.05 [Tables 8](#t8-cmar-10-5605){ref-type="table"}[](#t9-cmar-10-5605){ref-type="table"}[](#t10-cmar-10-5605){ref-type="table"}--[11](#t11-cmar-10-5605){ref-type="table"}; [Figures 2C](#f2-cmar-10-5605){ref-type="fig"}, [3C](#f3-cmar-10-5605){ref-type="fig"}, [4C](#f4-cmar-10-5605){ref-type="fig"}, and [5C](#f5-cmar-10-5605){ref-type="fig"}). By contrast, the LC3B−/TIGAR− (n=39), LC3B+/TIGAR+ (n=30), and LC3B+/TIGAR− (n=26) patterns each had a similarly favorable prognostic impact ([Figures 2C](#f2-cmar-10-5605){ref-type="fig"}, [3C](#f3-cmar-10-5605){ref-type="fig"}, [4C](#f4-cmar-10-5605){ref-type="fig"}, and [5C](#f5-cmar-10-5605){ref-type="fig"}). HRs are shown in [Tables 8](#t8-cmar-10-5605){ref-type="table"}[](#t9-cmar-10-5605){ref-type="table"}[](#t10-cmar-10-5605){ref-type="table"}--[11](#t11-cmar-10-5605){ref-type="table"}.

Discussion
==========

In this study, we investigated the expression levels of TIGAR and LC3B in NPC specimens, and their relationship with OS, LR-FFS, D-FFS, and FFS. Our results showed that negative LC3B expression and positive TIGAR expression were associated with a relatively poor prognosis. We therefore propose that TIGAR and LC3B may be indicators of prognosis in NPC patients.

Previous studies have found that TIGAR is highly expressed in certain tumor cell lines, including U2OS, RKO, and H1299, and regulates their growth and proliferation.[@b32-cmar-10-5605] Ye et al found that silencing TIGAR by RNA interference in Hep-G2 cells decreased TIGAR mRNA and protein levels and thereby inhibited cell proliferation, by inducing apoptosis and autophagy (*P*\<0.001).[@b19-cmar-10-5605] Cheung et al reported that TIGAR was dispensable in normal cell proliferation and development, but played a critical role in tumor generation; notably, they observed that deficient TIGAR expression reduced tumor burden and increased survival time in an intestinal adenoma mouse model.[@b22-cmar-10-5605] This indicates that TIGAR contributes to tumor progression and may be a potential therapeutic target for cancer treatment. In addition, high TIGAR expression has been identified in colon tumors,[@b19-cmar-10-5605] breast cancer,[@b24-cmar-10-5605] and glioblastoma,[@b23-cmar-10-5605] which suggests that upregulated TIGAR expression may contribute to cancer development.

Our previous study showed that TIGAR expression was elevated in NPC tissues, and silencing *TIGAR* by lentivirus-shRNA led to a decreased rate of tumor cell growth, proliferation, migration, and invasion, followed by an increase in the apoptosis rate of NPC cells.[@b33-cmar-10-5605] This indicated that TIGAR plays an important role in the growth, proliferation, and metastasis of NPC. In the present study, the relationship between TIGAR expression and the OS, LR-FFS, D-FFS, and FFS rates of NPC patients was evaluated via univariate and multivariate Cox regression analyses. The results showed that the TIGAR+ group is associated with a poorer outcome than the TIGAR− group. These findings suggest that TIGAR overexpression may be related to the prognosis of NPC, which is consistent with the previous reports.[@b19-cmar-10-5605],[@b22-cmar-10-5605]--[@b24-cmar-10-5605]

LC3B immunostaining has been reported to be generally higher in the majority of human cancer tissue types compared with their normal counterparts,[@b34-cmar-10-5605],[@b35-cmar-10-5605] including in head and neck cancer,[@b15-cmar-10-5605] esophageal adenocarcinomas,[@b13-cmar-10-5605],[@b36-cmar-10-5605] and early stage non-small-cell lung cancer.[@b37-cmar-10-5605] LC3B expression has also been demonstrated to be associated with cancer prognosis. In the present study, we used a univariate analysis to identify that the LC3B+ group had improved LR-FFS and FFS rates (*P*=0.027 and *P*=0.015, respectively, [Table 3](#t3-cmar-10-5605){ref-type="table"}) and tended toward improved D-FFS and OS, compared with the LC3B− group. Multivariate Cox proportional hazards analysis confirmed that LC3B expression was associated with LR-FFS and FFS. This was in accordance with the results of Schläfli et al.[@b37-cmar-10-5605] However, LC3B expression was not significantly associated with D-FFS. This may be due to the small sample size employed in the study. As autophagy has been reported to be related to cancer development, a large number of studies have studied the correlation between autophagy-related proteins and cancer prognosis. The results of research by Shereen Elmashed et al[@b38-cmar-10-5605] showed that a globular pattern of LC3B+expression predicted a better outcome in esophageal adenocarcinoma. Previous staining for LC3B has shown a cytoplasmic distribution,[@b34-cmar-10-5605],[@b39-cmar-10-5605] but here we failed to detect obvious distinctions among the LC3B staining patterns. The differences in antibody, cancer type, tumor stage, or tumor genetic context may account for such results.[@b11-cmar-10-5605],[@b40-cmar-10-5605]

In our study, the expression levels of TIGAR and LC3B were significantly correlated (*R*=−0.149, *P*=0.045, [Table 2](#t2-cmar-10-5605){ref-type="table"}). Therefore, we further combined the expression patterns of TIGAR and LC3B to analyze the relationship between their combined expression status and NPC outcomes. Kaplan-- Meier survival analysis demonstrated that patients with TIGAR+/LC3B− tumors had a relatively poor OS, FFS, D-FFS, and LR-FFS rates (all *P*\<0.05, [Table 3](#t3-cmar-10-5605){ref-type="table"}). The univariate and multivariate analyses also demonstrated a statistically significant relationship between LC3B−/TIGAR+ and OS, FFS, D-FFS, and LR-FFS rates. Thus, TIGAR+ and LC3B− expressions were associated with a relatively poor prognosis.

TIGAR+ alone was associated with a poor outcome in terms of D-FFS according to Kaplan--Meir survival analysis, log-rank test, and univariate Cox proportional hazards analysis (*P*=0.034, [Table 3](#t3-cmar-10-5605){ref-type="table"}), but multivariate Cox proportional hazards analysis showed that TIGAR was not an independent prognostic factor (HR =0.471, *P*=0.079; [Table 5](#t5-cmar-10-5605){ref-type="table"}) for D-FFS. In contrast, Cox proportional hazards analysis showed the combination of TIGAR+/LC3B− expression to be an independent prognostic factor (HR =2.744, *P*=0.008; [Table 9](#t9-cmar-10-5605){ref-type="table"}) for D-FFS. A previous study showed that the relationship between autophagy-related proteins and cancer prognosis was significantly different between various tumor types and cohorts.[@b41-cmar-10-5605] Moreover, autophagy is a dynamic process, which is positively or negatively regulated at several levels by autophagy-related proteins.[@b41-cmar-10-5605] Therefore, combining two or more autophagy-related proteins may better predict the role of autophagy in tumor development. In summary, combining data regarding the expression of TIGAR and LC3B in tumor tissue may have a more significant prognostic value than the expression of either protein alone.

A recent study reported that TIGAR could affect cancer cell survival and exert a dual role in anticancer therapy through regulating apoptosis and autophagy. *TIGAR* silencing resulted in increased LC3B, and conversely, overexpression of TIGAR correlated with decreased levels of LC3B.[@b16-cmar-10-5605] This suggested that TIGAR has a negative correlation with LC3B, and that the expression of TIGAR plays an anti-autophagy role in cancer cells, in accordance with the current study revealing a significant relationship between TIGAR and LC3B expression in NPC (*P*=0.045, *R*=−0.149, [Table 2](#t2-cmar-10-5605){ref-type="table"}). Xie et al[@b42-cmar-10-5605] reported that TIGAR silencing increased the activation of autophagy and could inactivate the mTOR pathway induced by epirubicin. Furthermore, in vivo suppression of TIGAR expression reduced tumorigenicity. Ting Ma et al[@b43-cmar-10-5605] revealed that *TIGAR* knockdown could increase physa pubenolide-induced apoptosis and autophagy-related cell death. These studies imply that the *TIGAR* gene through its protein inhibition of autophagy plays a significant role in cancer progression.

In summary, the role of autophagy is complex and paradoxical in tumorigenesis. Most studies support that autophagy can support cell survival in response to different stress conditions during cancer progression and treatment. Some studies have also found that defects in autophagy could promote tumor development. Previous study by our group showed that the autophagy activity and apoptosis rate of NPC cells were enhanced after silencing of *TIGAR*.[@b33-cmar-10-5605] Hence, we speculated that the autophagy process regulated by TIGAR may suppress the development of NPC cells. However, we still do not know the exact autophagy-related regulatory mechanism involved in the development of NPC, and thus will focus on this potential regulatory mechanism underlying pharyngeal cancer development in further research.

Conclusion
==========

In conclusion, TIGAR was frequently expressed in NPC tissues, and positive TIGAR expression was revealed to be associated with poor prognosis. These findings indicate that TIGAR is associated with the development of NPC, and may be a potential therapeutic target. We also examined the different expression patterns of TIGAR and LC3B in NPC tumors; TIGAR+ and LC3B− expressions were significantly associated with relatively poor prognosis in NPC, alone and in combination. The results of this study implied that TIGAR and LC3B may be a novel molecular target in the therapy for NPC.
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![Immunostaining of TIGAR and LC3B protein expressions in nasopharyngeal carcinoma.\
**Notes:** (**A)** TIGAR+ (×200); (**B)** TIGAR− (×200); (**C**) LC3B+ (×200); (**D**) LC3B− (×200).\
**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator.](cmar-10-5605Fig1){#f1-cmar-10-5605}

![Correlation of TIGAR and LC3B expressions with LR-FFS time.\
**Notes:** (**A**) Correlation between TIGAR expression and LR-FFS; (**B**) correlation between LC3B expression and LR-FFS; (**C**) correlation between TIGAR and LC3B expressions and LR-FFS.\
**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; LR-FFS, local regional failure-free survival; TIGAR, TP53-induced glycolysis and apoptosis regulator.](cmar-10-5605Fig2){#f2-cmar-10-5605}

![Correlation of TIGAR and LC3B expressions with D-FFS time.\
**Notes:** (**A**) Correlation between TIGAR expression and D-FFS; (**B**) correlation between LC3B expression and D-FFS; (**C**) correlation between TIGAR and LC3B expressions and D-FFS.\
**Abbreviations:** D-FFS, distant failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator.](cmar-10-5605Fig3){#f3-cmar-10-5605}

![Correlation of TIGAR and LC3B expressions with FFS time.\
**Notes:** (**A**) Correlation between TIGAR expression and FFS; (**B**) correlation between LC3B expression and FFS; (**C**) correlation between TIGAR and LC3B expressions and FFS.\
**Abbreviations:** FFS, failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator.](cmar-10-5605Fig4){#f4-cmar-10-5605}

![Correlation of TIGAR and LC3B expressions with OS time.\
**Notes:** (**A**) Correlation between TIGAR expression and OS; (**B**) correlation between LC3B expression and OS; (**C**) correlation between TIGAR and LC3B expressions and OS.\
**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; OS, overall survival; TIGAR, TP53-induced glycolysis and apoptosis regulator.](cmar-10-5605Fig5){#f5-cmar-10-5605}

###### 

Relationship between TIGAR and LC3B expressions and clinicopathologic variables in NPC

  Variables                               N of cases   TIGAR   *P*-value   N of cases   LC3B   *P*-value         
  --------------------------------------- ------------ ------- ----------- ------------ ------ ----------- ----- -------
                                                                                                                 
  **Gender**                                                                                                     
  Male                                    128          80      48          0.439        128    38          90    0.626
  Female                                  54           37      17                       54     18          36    
  **Age (years)**                                                                                                
  ≤48                                     96           61      35          0.825        96     30          66    0.882
  \>48                                    86           56      30                       86     26          60    
  **WHO pathology classification**                                                                               
  I (keratinizing)                        4            3       1           0.951        4      0           4     0.318
  II (nonkeratinizing)                    65           41      24                       113    33          80    
  III (undifferentiated)                  113          73      40                       65     23          42    
  **T stage**                                                                                                    
  T1--2                                   97           57      40          0.121        97     33          64    0.337
  T3--4                                   85           60      25                       85     23          62    
  **Lymph node metastasis**                                                                                      
  N0                                      33           22      11          0.842        33     15          18    0.06
  N1--3                                   149          95      54                       149    41          108   
  **TNM stage AJCC group (seventh ed)**                                                                          
  I--II                                   48           30      18          0.861        48     18          30    0.275
  III--IV                                 134          87      47                       134    38          96    

**Note:** Statistical analysis was estimated by chi-squared test, and *P*\<0.05 was considered statistically significant.

**Abbreviations:** AJCC, American Joint Committee on Cancer; LC3B, microtubule-associated protein 1 light chain 3; NPC, nasopharyngeal carcinoma; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

The correlation between TIGAR and LC3B expressions

             TIGAR   *R*   *P*-value   
  ---------- ------- ----- ----------- -------
                                       
  **LC3B**                             
  **+**      30      26    −0.149      0.045
  **−**      87      39                

**Notes:** Statistical analysis was estimated with Spearman correlation analysis, and *P*\<0.05 was considered statistically significant.

**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator.

###### 

The correlation between TIGAR and LC3B expressions in outcomes

  Variables                                OS n (%)     *P*-value   LR-FFS n (%)   *P*-value   D-FFS n (%)   *P*-value   FFS n (%)   *P*-value
  ---------------------------------------- ------------ ----------- -------------- ----------- ------------- ----------- ----------- -----------
                                                                                                                                     
  **Gender**                                                                                                                         
  Male                                     101 (78.9)   0.463       108 (84.4)     0.138       102 (79.7)    0.372       90 (70.3)   0.213
  Female                                   45 (83.3)                50 (92.6)                  46 (85.2)                 43 (79.6)   
  **Age (years)**                                                                                                                    
  ≤48                                      83 (86.5)    0.038       84 (87.5       0.79        81 (84.4)     0.219       74 (77.1)   0.204
  \>48                                     63 (73.3)                74 (86)                    67 (77.9)                 59 (68.6)   
  **WHO pathology classification**                                                                                                   
  I (keratinizing)                         4 (100)      0.586       4 (100)        0.719       4 (100)       0.633       4 (100)     0.441
  II (nonkeratinizing)                     54 (83.1)                56 (86.2)                  54 (83.1)                 50 (76.9)   
  III (undifferentiated)                   88 (77.9)                98 (86.7)                  90 (79.6)                 79 (69.9)   
  **T stage**                                                                                                                        
  T1--2                                    84 (86.6)    0.123       90 (92.8)      0.037       86 (88.7)     0.021       80 (82.5)   0.123
  T3--4                                    62 (72.9)                68 (80)                    62 (72.9)                 53 (62.4)   
  **Lymph node metastasis**                                                                                                          
  N0                                       84 (86.6)    0.153       90 (92.8)      0.037       86 (88.7)     0.021       80 (82.5)   0.014
  N1--3                                    62 (72.9)                68 (80)                    62 (72.9)                 53 (62.4)   
  **TNM stage AJCC group (seventh ed.)**                                                                                             
  I--II                                    39 (81.3)    0.629       46 (96)        0.088       41 (85.4)     0.662       39 (81.3)   0.388
  III--IV                                  107 (79.9)               112 (83.6)                 107 (79.9)                94 (70.1)   
  **TIGAR expression**                                                                                                               
  (+)                                      86 (73.5)    0.002       97 (82.9)      0.025       90 (76.9)     0.034       77 (65.8)   0.003
  (−)                                      60 (92.3)                61 (93.8)                  58 (89.2)                 56 (86.2)   
  **LC3B expression**                                                                                                                
  (+)                                      51 (91.1)    0.059       54 (96.4)      0.027       50 (89.3)     0.118       49 (87.5)   0.015
  (−)                                      95 (75.4)                104 (82.5)                 98 (77.8)                 84 (66.7)   
  **TIGAR (+) LC3B(**−**)/other case**                                                                                               
                                           58 (67.4)    \<0.05      68 (79.1)      0.002       62 (72.1)     0.002       50 (58.1)   \<0.05
                                           88 (91.7)                90 (93.8)                  86 (89.6)                 83 (86.6)   

**Notes:** Statistical analysis was estimated with log-rank, and *P*\<0.05 was considered statistically significant.

**Abbreviations:** AJCC, American Joint Committee on Cancer; D-FFS, distant failure-free survival; FFS, failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; LR-FFS, local regional failure-free survival; TIGAR, TP53-induced glycolysis and apoptosis regulator; OS, overall survival; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for LR-FFS rate

  Variable                                          Univariate analysis   Multivariate analysis                                         
  ------------------------------ ------------------ --------------------- ----------------------- ------- -------------- -------------- -------
                                                                                                                                        
  Age (years)                    ≤48 vs \>48        0.897                 0.402--2                0.791   0.939          0.408--2.165   0.505
  Sex                            Male vs Female     2.202                 0.752--6.443            0.15    1.876          0.611--5.755   0.141
  T stage                        T1--2 vs T3--4     0.404                 0.167--0.976            0.044   0.497          0.178--1.391   0.101
  N stage                        N0 vs N1--3        0.209                 0.028--1.549            0.126   0.229          0.03--1.742    0.081
  TNM stage                      I--II vs III--IV   0.305                 0.072--1.299            0.108   0.55           0.109--2.768   0.094
  WHO pathology classification   I                                                                0.941                                 0.887
  II                             0                  0                     0.983                   0       0              0.984          
  III                            1.159              0.506--2.654          0.727                   1.247   0.515--3.021   0.625          
  TIGAR expression               \+ vs −            0.315                 0.107--0.921            0.035   0.324          0.11--0.954    0.041
  LC3B expression                \+ vs −            4.433                 1.04--18.88             0.044   4.256          1--18.118      0.05

**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; LR-FFS, local regional failure-free survival; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization**.**

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for D-FFS rate

  Variable                                          Univariate analysis   Multivariate analysis                                        
  ------------------------------ ------------------ --------------------- ----------------------- ------- ------------- -------------- -------
                                                                                                                                       
  Age (years)                    ≤48 vs \>48        0.656                 0.333--1.293            0.223   0.688         0.342--1.387   0.251
  Sex                            Male vs Female     1.431                 0.648--3.162            0.376   1.262         0.549--2.899   0.37
  T stage                        T1--2 vs T3--4     0.438                 0.213--0.901            0.025   0.352         0.137--0.904   0.03
  N stage                        N0 vs N1--3        0.606                 0.213--1.723            0.348   0.539         0.185--1.565   0.266
  TNM stage                      I--II vs III--IV   0.832                 0.361--1.919            0.666   1.876         0.645--5.452   0.347
  WHO pathology classification   I                                                                0.971                                0.99
  II                             0                  0                     0.979                   0       0             0.978          
  III                            0.915              0.444--1.885          0.81                    1.054   0.492--2.26   0.891          
  TIGAR expression               \+ vs −            0.419                 0.182--0.963            0.041   0.471         0.204--1.092   0.079
  LC3B expression                \+ vs −            1.993                 0.824--4.824            0.126   1.968         0.809--4.791   0.177

**Abbreviations:** D-FFS, distant failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for FFS rate

  Variable                                          Univariate analysis   Multivariate analysis                                         
  ------------------------------ ------------------ --------------------- ----------------------- ------- -------------- -------------- -------
                                                                                                                                        
  Age (years)                    ≤48 vs \>48        0.696                 0.396--1.224            0.208   0.699          0.389--1.259   0.118
  Sex                            Male vs Female     1.524                 0.779--2.983            0.218   1.366          0.67--2.785    0.17
  T stage                        T1--2 vs T3--4     0.485                 0.269--0.876            0.016   0.567          0.312--1.032   0.063
  N stage                        N0 vs N1--3        0.528                 0.209--1.335            0.177   0.494          0.191--1.275   0.14
  TNM stage                      I--II vs III--IV   0.729                 0.353--1.507            0.394   1.327          0.545--3.231   0.704
  WHO pathology classification   I                                                                0.836                                 0.94
  II                             0                  0                     0.974                   0       0              0.974          
  III                            0.83               0.451--1.529          0.551                   0.891   0.468--1.698   0.727          
  TIGAR expression               \+ vs --           0.35                  0.17--0.722             0.004   0.403          0.193--0.84    0.015
  LC3B expression                \+ vs --           2.591                 1.162--5.778            0.02    2.428          1.089--5.412   0.03

**Abbreviations:** FFS, failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for OS rate

  Variable                                          Univariate analysis   Multivariate analysis                                        
  ------------------------------ ------------------ --------------------- ----------------------- ------- ------------- -------------- -------
                                                                                                                                       
  Age (years)                    ≤48 vs \>48        0.495                 0.251--0.978            0.043   0.432         0.218--0.858   0.016
  Sex                            Male vs Female     1.324                 0.622--2.185            0.466   1.085         0.495--2.378   0.917
  T stage                        T1--2 vs T3--4     0.584                 0.295--1.154            0.122   0.455         0.176--1.175   0.44
  N stage                        N0 vs N1--3        0.435                 0.133--1.42             0.168   0.387         0.117--1.28    0.202
  TNM stage                      I--II vs III--IV   1.2                   0.562--2.562            0.638   2.381         0.85--6.664    0.463
  WHO pathology classification   I                                                                0.927                                0.951
  II                             0                  0                     0.978                   0       0             0.977          
  III                            0.868              0.426--1.768          0.697                   0.886   0.42--1.872   0.752          
  TIGAR expression               \+ vs --           0.257                 0.1--0.661              0.005   0.25          0.097--0.646   0.004
  LC3B expression                \+ vs --           2.414                 0.937--6.217            0.068   2.521         0.974--6.521   0.057

**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; OS, overall survival; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for LR-FFS rate

                                                                     Univariate analysis   Multivariate analysis                                         
  ------------------------------------ ----------------------------- --------------------- ----------------------- ------- -------------- -------------- -------
  Age (years)                          ≤48 vs \>48                   0.897                 0.402--2                0.791   0.946          0.412--2.173   0.635
  Sex                                  Male vs female                2.202                 0.752--6.443            0.15    1.854          0.61--5.638    0.218
  T stage                              T1--2 vs T3--4                0.404                 0.167--0.976            0.044   0.458          0.188--1.118   0.086
  N stage                              N0 vs N1--3                   0.209                 0.028--1.549            0.126   0.179          0.024--1.325   0.092
  TNM stage                            I--II vs III--IV              0.305                 0.072--1.299            0.108   0.535          0.106--2.686   0.419
  WHO pathology classification         I                                                                           0.941                                 0.912
  II                                   0                             0                     0.983                   0       0              0.983          
  III                                  1.159                         0.506--2.654          0.727                   1.211   0.505--2.906   0.668          
  Correlation between TIGAR and LC3B   TIGAR(+) LC3B(−)/other case   3.86                  1.53--9.373             0.004   3.561          1.394--9.098   0.008

**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; LR-FFS, local regional failure-free survival; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for D-FFS rate

                                                                    Univariate analysis   Multivariate analysis                                         
  ------------------------------------ ---------------------------- --------------------- ----------------------- ------- -------------- -------------- -------
  Age (years)                          ≤48 vs \>48                  0.656                 0.333--1.293            0.223   0.67           0.334--1.347   0.152
  Sex                                  Male vs female               1.431                 0.648--3.162            0.376   1.263          0.553--2.886   0.332
  T stage                              T1--2 vs T3--4               0.438                 0.213--0.901            0.025   0.505          0.244--1.045   0.066
  N stage                              N0 vs N1--3                  0.606                 0.213--1.723            0.348   0.506          0.175--1.463   0.244
  TNM stage                            I--II vs III--IV             0.832                 0.361--1.919            0.666   1.812          0.628--5.227   0.367
  WHO pathology classification         I                                                                          0.971                                 0.997
  II                                   0                            0                     0.979                   0       0              0.978          
  III                                  0.915                        0.444--1.885          0.81                    1.027   0.481--2.193   0.944          
  Correlation between TIGAR and LC3B   TIGAR(+)LC3B(−)/other case   3.021                 1.444--6.32             0.003   2.744          1.303--5.777   0.008

**Abbreviations:** D-FFS, distant failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for FFS rate

                                                                    Univariate analysis   Multivariate analysis                                             
  ------------------------------------ ---------------------------- --------------------- ----------------------- ----------- -------------- -------------- -----------
  Age (years)                          ≤48 vs \>48                  0.696                 0.396--1.224            0.208       0.699          0.389--1.259   0.128
  Sex                                  Male vs female               1.524                 0.779--2.983            0.218       1.366          0.67--2.785    0.263
  T stage                              T1--2 vs T3--4               0.485                 0.269--0.876            0.016       0.532          0.291--0.972   0.04
  N stage                              N0 vs N1--3                  0.528                 0.209--1.335            0.177       0.438          0.173--1.105   0.08
  TNM stage                            I--II vs III--IV             0.729                 0.353--1.507            0.394       1.285          0.529--3.118   0.52
  WHO pathology classification         I                                                                          0.836                                     0.092
  II                                   0                            0                     0.974                   0           0              0.974          
  III                                  0.83                         0.451--1.529          0.551                   0.946       0.509--1.758   0.861          
  Correlation between TIGAR and LC3B   TIGAR(+)LC3B(−)/other case   3.694                 1.957--6.97             5.50E--05   3.639          1.918--6.906   5.50E--05

**Abbreviations:** FFS, failure-free survival; LC3B, microtubule-associated protein 1 light chain 3; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.

###### 

Univariate and multivariate Cox proportional hazard analyses of clinicopathologic variables for OS rate

                                                                    Univariate analysis   Multivariate analysis                                             
  ------------------------------------ ---------------------------- --------------------- ----------------------- ----------- -------------- -------------- -----------
  Age (years)                          ≤48 vs \>48                  0.495                 0.251--0.978            0.043       0.454          0.228--0.905   0.025
  Sex                                  Male vs female               1.324                 0.622--2.185            0.466       1.069          0.489--2.338   0.962
  T stage                              T1--2 vs T3--4               0.584                 0.295--1.154            0.122       0.46           0.181--1.164   0.101
  N stage                              N0 vs N1--3                  0.435                 0.133--1.42             0.168       0.387          0.117--1.28    0.202
  TNM stage                            I--II vs III--IV             1.2                   0.562--2.562            0.638       2.402          0.862--6.692   0.094
  WHO pathology classification         I                                                                          0.927                                     0.954
  II                                   0                            0                     0.978                   0           0              0.977          
  III                                  0.868                        0.426--1.768          0.697                   0.89        0.423--1.874   0.759          
  Correlation between TIGAR and LC3B   TIGAR(+)LC3B(−)/other case   4.285                 1.95--9.416             2.91E--04   4.338          1.944--9.677   2.26E--04

**Abbreviations:** LC3B, microtubule-associated protein 1 light chain 3; OS, overall survival; TIGAR, TP53-induced glycolysis and apoptosis regulator; WHO, World Health Organization.
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